Amatu, A <br/><br/>
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  06 2016 
 - 1062-1067 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw071  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers, Tumor--blood<br/>Biopsy<br/>Colorectal Neoplasms--blood<br/>DNA Methylation--genetics<br/>DNA Modification Methylases--blood<br/>DNA Repair Enzymes--blood<br/>Dacarbazine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Promoter Regions, Genetic<br/>Temozolomide<br/>Tumor Suppressor Proteins--blood